Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

Cytovance Biologics, a CDMO specializing in therapeutic protein and antibody manufacturing using mammalian cell culture and microbial fermentation, headquartered in Oklahoma City, Oklahoma, has launched in-house cell line development services , adding upstream capabilities to its biologics development and manufacturing platform. The cell line development platform uses CHO expression systems and has demonstrated titers up to 10 g/L for monoclonal antibodies, according to the announcement. The addition builds on Cytovance’s recent launch of formulation development capabilities and is designed to give customers an integrated path from DNA through IND submission without requiring external technology transfers, the company said. Shelly Gulati, senior scientist of mammalian process development at Cytovance, said in a statement bringing cell line development in-house allows the company to provide clients with an integrated experience, eliminating external handoffs and enabling faster, data-driven decisions that strengthen manufacturability from the start. Ping Zhang, CEO of Cytovance Biologics, added that the addition of cell line development helps clients move from concept to clinic while eliminating development barriers and improving process continuity. The launch follows Cytovance’s April agreement with Anixa Biosciences to produce cGMP clinical materials for a planned Phase II trial of Anixa’s investigational breast cancer vaccine, which targets alpha-lactalbumin, a protein that can reappear in some forms of breast cancer, and generated protocol-defined immune responses in 74% of participants in Phase I trials.

OKLAHOMA CITY--(BUSINESS WIRE)--Cytovance Biologics®, a leading US-based contract development and manufacturing organization (CDMO) serving the biopharmaceutical industry, today announced the expansion of its mammalian cell culture capabilities with the addition of cell line development services, strengthening its ability to provide a seamless path from DNA to IND submission for its customers. The launch of new cell line development services reflects Cytovance’s continued investment in innovation and its commitment to evolving alongside the needs of its partners. Building on the recent launch of formulation development capabilities, the addition of in-house cell line development further strengthens Cytovance’s integrated offering—enabling a more seamless, efficient, and forward-looking approach to biologics development from discovery through commercialization. “Our clients are looking for high-yield, speed and continuity,” said Shelly Gulati, Senior Scientist, Mammalian Process Development at Cytovance Biologics. “Bringing cell line development in-house allows us to provide them with a truly integrated ‘one-stop-shop’ experience, eliminating external handoffs, and making faster, data-driven decisions that strengthen manufacturability from the start.” With headline titers reaching up to 10 g/L for monoclonal antibodies, Cytovance enters the cell line development market as one of the leading performers in CHO expression systems. The platform’s consistently high titers enable faster process development, reduce manufacturing costs per gram, and accelerate timelines without compromising product quality. “Two decades ago, Cytovance was founded on an ambitious vision: to help partners worldwide transform scientific breakthroughs into life-changing therapies,” said Ping Zhang, CEO of Cytovance Biologics. “Today, that vision is thriving. By offering in-house cell line development, we are helping clients move from concept to clinic, eliminating barriers, unlocking productivity and building a smarter, more resilient development path.” For more information about Cytovance Biologics, visit . About Cytovance: Cytovance Biologics is an established large molecule CDMO that is large enough to support you at every stage and small enough to stay agile, providing your program with the care it deserves. For 20 years, Team Cytovance has offered flexibility and ingenuity across a full range of integrated services, supporting mammalian- and microbial-derived products on their journey from molecule to commercial manufacturing. Follow us on LinkedIn: @Cytovance Biologics Contacts Emily Steinhauer Esteinhauer@cglife.com 2032189906

Calgary, Alberta--(News - May 11, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announced today a one-year extension of the Company's US$6.0 million secured debenture with Shenzhen Hepalink Pharmaceutical Group Co., Ltd. ("Hepalink") (and payment of accrued interest thereon), extending the maturity date to May 13, 2027. In connection with the extension, the interest rate has been amended from 18% to 20% per annum, commencing on May 14, 2026. "We appreciate Hepalink's continued support and are pleased with the one-year extension of the debenture," stated Donald McCaffrey, President & CEO of Resverlogix. About Resverlogix Founded in 2001, Resverlogix is a Calgary based late-stage biotechnology company, and a world leader in epigenetics, with the goal of developing first-in-class therapies for the benefit of patients with chronic disease. Resverlogix is developing a new class of epigenetic therapies designed to regulate the expression of disease-causing genes. We aim to improve patients' lives by restoring biological functions - altered by serious illnesses such as cardiovascular disease - back to a healthier state. The Company's clinical program is focused on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post COVID-19 conditions. Resverlogix common shares trade on the Toronto Stock Exchange (TSX: RVX). Follow us on: X.com: @Resverlogix_RVX LinkedIn: linkedin.com/company/resverlogix-corp-/ Forward-Looking Statements: This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts", and other similar expressions. In particular, this news release includes forward looking information related to the potential role of apabetalone in the treatment of patients with cardiovascular disease, post COVID-19 conditions, pulmonary arterial hypertension, associated comorbidities, and other chronic diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at . The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. For further information please contact: Investor Relations Email: ir@resverlogix.com Phone: 403-254-9252 To view the source version of this press release, please visit